Metabolic Profiling and Perturbations of Human CD34+ Hematopoietic Stem and Progenitors to Regulate HSPC Function [0.03%]
人类CD34+造血干细胞和祖细胞的代谢轮廓和代谢紊乱可调节HSPC功能
Kai Yuan,Mingfang Xiong,Rong Yang et al.
Kai Yuan et al.
Hematopoietic stem cells (HSCs) possess self-renewal and multilineage differentiation abilities to generate blood cells and sustain hematopoiesis. Recent studies indicate that HSC metabolism is crucial for regulating their function and cell...
Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONE [0.03%]
达雷妥尤单抗治疗新诊断多发性骨髓瘤患者的感染问题：MAIA和ALCYONE研究的汇总分析
Nizar J Bahlis,Thierry Facon,Jesús F San-Miguel et al.
Nizar J Bahlis et al.
Both the phase 3 MAIA and ALCYONE studies demonstrated significant survival benefit with the addition of daratumumab to standard-of-care lenalidomide and dexamethasone (D-Rd) or bortezomib, melphalan, and prednisone (D-VMP), respectively, v...
Toxicity from asparaginase during acute lymphoblastic leukemia induction: A report from the Children's Oncology Group [0.03%]
儿童急性淋巴细胞白血病诱导期Asparaginase毒性反应的报道-儿童肿瘤联盟报告
Etan Orgel,Luke D Maese,Meenakshi Devidas et al.
Etan Orgel et al.
Asparaginase-associated toxicities (AAT) often compromise therapy for acute lymphoblastic leukemia (ALL), impacting relapse risk and survival. There are conflicting data on the contributions of older age, obesity by body mass index (BMI), a...
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma [0.03%]
同种异体CD19靶向CAR-T细胞治疗CTX110治疗复发/难治B细胞非霍奇金淋巴瘤的安全性与疗效研究
Joseph P McGuirk,Armin Ghobadi,Carlos R Bachier et al.
Joseph P McGuirk et al.
This multicenter, single-arm, phase 1/2 study evaluated the safety and efficacy of CD19-directed allogeneic chimeric-antigen-receptor (CAR) immunotherapy CTX110 in adult patients with relapsed/refractory (r/r) B-cell non-Hodgkin lymphoma (N...
Long-distance trail running induces functional iron deficiency driven by inflammation [0.03%]
长距离越野跑引起的炎症介导的功能性缺铁
Anna Katharina Tobiasch,Tobias Dünnwald,Paolo Emilio Adami et al.
Anna Katharina Tobiasch et al.
Iron is a critical cofactor for numerous cellular processes, particularly mitochondrial oxidative phosphorylation. Functional iron deficiency, often driven by inflammation-induced hepcidin upregulation, restricts iron availability to periph...
Polatuzumab vedotin-containing regimens as bridge to CART: analysis from the CART-SIE study [0.03%]
多妥珠单抗维多汀桥接CAR-T的预处理方案：CART-SIE研究分析
Giulia Gabrielli,Beatrice Casadei,Annalisa Chiappella et al.
Giulia Gabrielli et al.
High tumor burden negatively affects responses to anti-CD19 chimeric antigen receptor T-cell (CART) therapy in large B-cell lymphoma (LBCL). Therefore, bridging therapy (BT) is crucial for disease control before infusion. Here, we retrospec...
LYP vs. advanced-stage CTCLs: Single-cell profiling reveals markers of self-limited vs. aggressive disease behavior [0.03%]
LYP与晚期CTCL的单细胞谱型分析：发现自限性疾病与侵袭性疾病的标志物
Shannon Meledathu,Sumanth Chennareddy,Malini P Naidu et al.
Shannon Meledathu et al.
Cutaneous T-cell lymphomas (CTCL) encompass a broad spectrum from highly indolent to aggressive systemic disease, but underlying mechanisms remain only poorly understood. Using single-cell RNA sequencing (scRNA-seq), we profiled samples fro...
Combining Menin and MEK inhibition to target poor prognosis KMT2A-rearranged RAS pathway-mutant acute myeloid leukemia [0.03%]
联合使用Menin和MEK抑制剂靶向不良预后的KMT2A重排RAS途径突变急性髓系白血病
Nastassja Keora Scheidegger,Constanze Schneider,Gabriela Alexe et al.
Nastassja Keora Scheidegger et al.
KMT2A-rearranged (KMT2A-r) acute leukemias are especially prevalent in the pediatric population. KMT2A-fusion proteins drive leukemogenic gene expression through an interaction with a chromatin complex that includes the scaffold protein men...
Dual action of pimozide through lysosome disruption and inhibition of STATs induces apoptosis in chronic lymphocytic leukemia (CLL) [0.03%]
穿孔素通过溶酶体破坏和STAT抑制诱导慢性淋巴细胞白血病(CLL)凋亡的双重作用
Spencer B Gibson,Madhumita S Manivannan,Xiaoyan Yang et al.
Spencer B Gibson et al.
Chronic lymphocytic leukemia (CLL) progression and therapeutic resistance are driven in large part by protective signals from the tumor microenvironment (TME), which includes T-cell-derived cytokines such as interleukin-4 (IL-4) that promot...
Alan B Cantor,Akiko Shimamura
Alan B Cantor